Clinical Trials for Ovarian Cancer

A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors, initially ovarian cancer and endometrial carcinoma, receive IV HWK-016, a first-in-human MUC16-directed antibody–drug conjugate carrying a topoisomerase I inhibitor payload. Ovarian cancer cohorts may also receive HWK-016 combined with bevacizumab, with dose escalation/expansion focused on safety, recommended dose, pharmacokinetics, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT07470853

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable recurrent, locally advanced, or metastatic solid tumors, including endometrial and ovarian cancers, receive DBC-664 monotherapy in dose-escalation or expansion cohorts. DBC-664 is an investigational biologic with an undisclosed molecular target and mechanism of action.

ClinicalTrials.gov ID: NCT07705035

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adult women with relapsed/refractory ovarian carcinoma or carcinosarcoma after standard therapies receive single-agent NTB-928, including those with platinum-resistant/refractory disease or platinum-sensitive disease ineligible for further platinum. NTB-928 is a fully human bispecific T-cell engager targeting FRα/FOLR1 on tumor cells and CD3 on T cells to promote immune-mediated tumor killing.

ClinicalTrials.gov ID: NCT07690189

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant epithelial ovarian, primary peritoneal, or fallopian-tube cancer receive autologous GB-5267, an IL-18–secreting CAR T-cell therapy targeting membrane-bound MUC16. Dose escalation uses intravenous administration, followed by expansion evaluating combined intravenous and intraperitoneal delivery.

ClinicalTrials.gov ID: NCT07489287

A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.

ClinicalTrials.gov ID: NCT07749586

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer, or endometrial cancer, receive ARR-002 in dose-escalation or expansion cohorts. ARR-002 is an investigational antibody–drug conjugate targeting MUC16 and NaPi2b that delivers the microtubule-disrupting payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT07755436

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced selected solid tumors who have exhausted or are ineligible for standard treatment receive oral TT-10 (PORT-6), an adenosine A2A receptor antagonist, oral TT-4 (PORT-7), an adenosine A2B receptor antagonist, or both. Eligible tumor types vary by cohort and include RCC, CRPC, NSCLC, head and neck, colorectal, endometrial, and ovarian cancers.

ClinicalTrials.gov ID: NCT04969315

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic or unresectable cancer, ECOG 0–1, and no suitable standard treatment option may receive oral NX-1607, a CBL-B inhibitor intended to enhance T-cell antitumor activity. Selected tumor cohorts receive NX-1607 with paclitaxel.

ClinicalTrials.gov ID: NCT05107674

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.

ClinicalTrials.gov ID: NCT03556228

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic cancer after progression on, intolerance of, or lack of benefit from standard therapy receive oral AMXI-5001 twice daily as monotherapy. AMXI-5001 is an investigational dual inhibitor of PARP1/2-mediated DNA repair and tubulin polymerization.

ClinicalTrials.gov ID: NCT04503265